Prostamax vs Testagen — Peptide Comparison

At a Glance

Quickcomparison

Dose Range

Prostamax

5–10 mg

Testagen

Frequency

Once daily

Administration

Sublingual (enteric-coated capsules)

Cycle Length

12+ weeks

Onset Speed

Gradual (3-4 weeks)

Evidence Level

Limited human trials

Efficacy

Benefitratings

Prostate Health

Urinary Function

Tissue Inflammation

Testosterone Support

Male Aging Health

Reproductive Function

Technical Data

Compoundspecifications

Molecular Formula

C20H33N5O9

Molecular Weight

487.5 g/mol

Half-Life

Short plasma half-life typical of tetrapeptides (minutes to hours); biological effects persist for weeks to months through chromatin remodeling at prostate gene promoters; metabolized to constituent amino acids

Bioavailability

Absorbed via intestinal peptide transporters (PepT1) in oral formulation; rapid absorption from subcutaneous injection sites; efficient cellular uptake due to short tetrapeptide structure with proline conferring conformational stability

CAS Number

Not publicly registered

C17H29N5O9

447.4 g/mol

Short plasma half-life typical of tetrapeptides (minutes to hours); biological effects persist for weeks to months through epigenetic modifications to testicular gene expression; metabolized to constituent amino acids

Absorbed via intestinal peptide transporters (PepT1) in oral formulation; rapid absorption from subcutaneous injection sites; efficient cellular uptake and nuclear penetration due to short tetrapeptide structure

Protocols

Dosingtiers

standard

0.01-100 mcg/kg

10-40 days

Dose from a single-institute patent report in 35 chronic-prostatitis patients [6]. The wide range reflects dose-finding within that single report.

~10 mg

10-30 day course

Capsule form reflecting bioregulator product labeling and practice [1].

starting

5-10 mg

10-day course

Injectable course used in practice; repeat after 3-6 months [1].

10 mg (2 x 5 mg capsules)

10 days (maintenance) up to 30 days (therapeutic) per course

Khavinson cytogen taken as enteric capsules; repeat course every 3-6 months [1].

Applications

Bestsuited for

Age-related benign prostatic hyperplasia (BPH) requiring tissue-level normalization

Prostamax is particularly well-suited for individuals focused on age-related benign prostatic hyperplasia (bph) requiring tissue-level normalization. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Prostate geroprotection — preserving prostatic epithelial function during aging

Prostamax is particularly well-suited for individuals focused on prostate geroprotection — preserving prostatic epithelial function during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Chronic prostatitis support through anti-inflammatory tissue-level mechanisms

Prostamax is particularly well-suited for individuals focused on chronic prostatitis support through anti-inflammatory tissue-level mechanisms. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Comprehensive Khavinson bioregulator protocols targeting male genitourinary health

Prostamax is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting male genitourinary health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Age-related testosterone decline (andropause) requiring physiological restoration rather than replacement

Testagen is particularly well-suited for individuals focused on age-related testosterone decline (andropause) requiring physiological restoration rather than replacement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

HPG axis normalization in aging males with suboptimal hormonal signaling

Testagen is particularly well-suited for individuals focused on hpg axis normalization in aging males with suboptimal hormonal signaling. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Comprehensive Khavinson bioregulator protocols targeting male reproductive health

Testagen is particularly well-suited for individuals focused on comprehensive khavinson bioregulator protocols targeting male reproductive health. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Testicular geroprotection — preserving Leydig and Sertoli cell function during aging

Testagen is particularly well-suited for individuals focused on testicular geroprotection — preserving leydig and sertoli cell function during aging. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.

Safety Profile

Sideeffects

Common

Injection site reaction

Mild fatigue

Urinary frequency changes

Mild headache

Uncommon

Mild pelvic discomfort

Serious

No documented serious adverse effects

Libido fluctuation

Mild acne or skin oiliness

Research Status

Safety& evidence

FDA Status

Research compound

Safety Overview

Prostamax (proprietary peptide blend) demonstrates limited published safety data; primarily used in clinical practice based on observational evidence. No serious adverse events reported in clinical use; mild gastrointestinal tolerance issues occasionally reported. Derived from bovine prostatic tissue; potential allergenicity in beef-sensitive individuals requires screening. Quality control and standardization vary across manufacturers.

Contraindications

xKnown or suspected prostate cancer — potential modulation of prostatic gene expression requires oncological clearance

xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, proline)

xSevere urinary retention requiring surgical intervention — epigenetic therapy cannot address acute obstruction

xConcurrent anti-androgen therapy without medical supervision — potential interaction with hormonal mechanisms

Testagen (lyophilized peptide complex) lacks published human safety data—all information derives from unpublished manufacturer data and theoretical extrapolation from rat studies. As an androgen secretagogue, it carries class risks including erythrocytosis (elevated red blood cell count), liver enzyme elevation, lipid profile unfavorable changes (reduced HDL, increased LDL), and prostate-related effects including urinary obstruction and potential malignancy acceleration. Cardiovascular risk including hypertension and increased thrombotic events are theoretical concerns based on androgen class pharmacology.

xKnown hypersensitivity to peptide bioregulators or constituent amino acids (lysine, glutamic acid, aspartic acid, glycine)

xHormone-sensitive cancers (prostate, testicular) — potential stimulation of androgen-dependent pathways

xPregnancy and breastfeeding (female partners) — not applicable for direct use but consider reproductive implications

xSevere hepatic or renal impairment — peptide metabolism may be altered

Decision Guide

Which isright for you?

Choose Prostamax if...

Age-related benign prostatic hyperplasia (BPH) requiring tissue-level normalization

Prostate geroprotection — preserving prostatic epithelial function during aging

Chronic prostatitis support through anti-inflammatory tissue-level mechanisms

Comprehensive Khavinson bioregulator protocols targeting male genitourinary health

Choose Testagen if...

Age-related testosterone decline (andropause) requiring physiological restoration rather than replacement

HPG axis normalization in aging males with suboptimal hormonal signaling

Comprehensive Khavinson bioregulator protocols targeting male reproductive health

Testicular geroprotection — preserving Leydig and Sertoli cell function during aging